Boston Scientific Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Boston Scientific Corporation's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
- Debt Due Cover Ratio: Debt due within a year is covered 15.2 times by its yearly operating cash. Higher than 88% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $42 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 86% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$165Over the last 3 years, every $100 of reported profit came with $165 of operating cash.
Higher than 59% of Healthcare companies in United States.
Self-Funding Ratio
3.5×Over the last 3 years its own operating cash covered its investment spending (capex) 3.5 times.
Higher than 81% of Healthcare companies in United States.
Cash Locked Ratio
$24For every $100 of sales, $24 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $22 tied up three years earlier.
More money tied up than 50% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$30Sales grew 58% in 3 years; of every extra $100 of sales, $30 became extra profit.
Higher than 57% of Healthcare companies in United States.
Asset Productivity Ratio
+58% / +35%In 3 years sales changed by +58% while total assets changed by +35%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
15.2×Debt due within a year is covered 15.2 times by its yearly operating cash.
Higher than 88% of Healthcare companies in United States.
Cash Cushion Ratio
−14%Debt, after subtracting cash, equals 14% of its market value (net debt).
Lower than 81% of Healthcare companies in United States.
Tangible Assets Ratio
42%Of every $100 the company owns, $42 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 86% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 75% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Boston Scientific Corporation owes $0.44 for every $1 it owns. Net profit rose 56% in the year to Dec 2025, and grew 61% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
18.6Investors pay $18.6 for every $1 of Boston Scientific Corporation's yearly profit, lower than 68% of Healthcare companies in United States.
P/B ratio
2.67The share price is 2.67 times Boston Scientific Corporation's book value per share, higher than 52% of Healthcare companies in United States.
Market cap
$66.7 BThe total market value of all of Boston Scientific Corporation's shares at today's price (share price × number of shares), larger than 97% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$24.9 BWhat Boston Scientific Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$17.20Net worth divided by the number of shares. The share price of $46.01 is 2.7 times this, which is the P/B above.
Return on equity (ROE)
15.3%Boston Scientific Corporation earned 15.3% on its shareholders' money over the last year, higher than 87% of Healthcare companies in United States.
Owes vs Owns
0.44×Boston Scientific Corporation owes $0.44 for every $1 it owns (low), higher than 51% of Healthcare companies in United States.
Dividend yield
NoneBoston Scientific Corporation does not currently pay a dividend.
Revenue growth
+20%Revenue rose 20% in the year to Dec 2025, and grew 17% a year on average over 3 years.
Profit growth
+56%Net profit rose 56% in the year to Dec 2025, and grew 61% a year on average over 3 years.
Profit margin
14.4%Boston Scientific Corporation keeps $14 of every $100 of revenue as net profit.
Cash quality
1.6×Cash from Boston Scientific Corporation's business was 1.6× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
11.4×Boston Scientific Corporation's operating profit covered its interest costs 11.4 times in the year to Dec 2025.
Cash vs debt
Net debtBoston Scientific Corporation had $9.5 B more debt than cash (net debt) at Dec 2025.
Questions
What is Boston Scientific Corporation's P/E ratio?
Investors pay $18.6 for every $1 of Boston Scientific Corporation's yearly profit, lower than 68% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Boston Scientific Corporation: $66.7 B ÷ $24.9 B (30 Jun 2026) = 2.7.
What is Boston Scientific Corporation's return on equity?
Boston Scientific Corporation earned 15.3% on its shareholders' money over the last year, higher than 87% of Healthcare companies in United States.
How much does Boston Scientific Corporation owe compared with what it owns?
Boston Scientific Corporation owes $0.44 for every $1 it owns (low), higher than 51% of Healthcare companies in United States.
Does Boston Scientific Corporation pay a dividend?
No. Boston Scientific Corporation does not currently pay a dividend.
Is Boston Scientific Corporation's revenue growing?
Revenue rose 20% in the year to Dec 2025, and grew 17% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.